The American biotech company Moderna announced Tuesday, May 25 that its vaccine against Covid-19 was "
highly effective
" in adolescents aged 12 to 17, according to full results of clinical trials.
To discover
Covid-19: vaccination as the only remedy
Read also: Why should children be vaccinated to do without barrier gestures
Moderna says it plans to file an application for authorization to use its vaccine for this age group "at the
beginning of June
" with "
regulators around the world
".
Another vaccine, that of Pfizer / BioNTech, is already authorized for adolescents in several countries, including the United States.
"
We are encouraged that the vaccine has been shown to be highly effective in preventing Covid-19 in adolescents,
" said Stéphane Bancel, boss of Moderna, quoted in a statement.
“
We will be submitting these results to the FDA (the US Medicines Agency) and regulators around the world in early June and seek clearance.
"
Moderna's study involved more than 3,700 participants aged 12 to 17 in the United States, two-thirds of whom received the vaccine, and one-third received a placebo. "
After two doses, no case of Covid-19 was observed in the vaccinated group against 4 cases in the placebo group, resulting in a vaccine efficacy of 100% 14 days after the second dose,
" Moderna said in his communicated. After a dose, an efficacy of 93% was observed, specifies the company. The vaccine was "
generally well tolerated
" and "
no concerns about its safety have been identified so far,
" said Moderna. The side effects observed were the same as in adults (pain at the site of the injection, fatigue, chills, etc.).
